Troxyca extended-release tablets are intended to treat patients that require daily, long-term opioid treatment to manage severe pain.
The tablets contain pellets of oxycodone hydrochloride, an opioid agonist, that surround naltrexone hydrochloride, an opioid antagonist.
When the pill is taken whole, the naltrexone remains sequestered and patients receive an extended-release dose of oxycodone. However, if the pill is crushed, the pellets release naltrexone, which counteracts the effects of the oxycodone.
Pfizer warns that while the drug is intended to reduce inappropriate use of the drug, opioid abuse is still possible.
The New York-based drugmaker did not say when the product would launch.
More articles on supply chain:
4 ways the FDA is contributing to high generic drug costs
Supply chain tip of the week: Replenish your inventory the right way
Researchers develop new method to transfer device data to smartphones
Becker’s 3rd Annual Fall Chief Pharmacy Officer Summit is the top tier event that the people leading the future of pharmacy convene. This 3-day event is built specifically for Chief Pharmacy Officers and senior pharmacy leaders. The sessions examine the workforce, financial and clinical priorities shaping pharmacy today. Becker’s is where candid discussions flourish and new ideas thrive. Becker's 3rd Annual Fall Chief Pharmacy Officer Summit
